300759SZSE

2025 Annual Independent Non-Executive Director Performance Report (Li Lihua)

Pharmaron Beijing Co., Ltd.··9 pages

✨ AI Summary

This report details the performance of Li Lihua, an Independent Non-Executive Director of Kanglonghua (Beijing) New Drug Technology Co., Ltd., for the year 2025. It covers her attendance at meetings, fulfillment of duties, and focus areas, emphasizing her commitment to safeguarding shareholder interests, particularly those of small and medium shareholders. The report confirms her independent status and adherence to regulations.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Kanglonghua (Beijing) New Drug Technology Co., Ltd. 2025 Annual Independent Non-Executive Director Performance Report (Independent Non-Executive Director: Li Lihua)

To the Shareholders and Shareholder Representatives:

As an Independent Non-Executive Director of Kanglonghua (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as the "Company"), I have, during the year 2025, strictly adhered to the Company Law, the Guiding Principles on Corporate Governance, the Administrative Measures for Independent Directors of Listed Companies, the Shenzhen Stock Exchange GEM Listing Rules for Regulated Operations, the Hong Kong Stock Exchange Listing Rules, and other relevant laws, regulations, normative legal documents, and the Company's Articles of Association and the Independent Non-Executive Director Work System. I have actively attended the Company's general meetings, board meetings, and special committee meetings, diligently reviewed all proposals, made prudent decisions, and paid close attention to the Company's development. I have promptly understood the Company's production and operation information, faithfully performed my duties as an Independent Non-Executive Director, acted diligently and conscientiously, and fully leveraged my independence and professional expertise to contribute to the Company's standardized, stable, and healthy development. I have effectively protected the legitimate rights and interests of the Company and all shareholders, especially small and medium shareholders. Herein is my report on my performance in 2025:

I. Basic Information of Independent Non-Executive Director

(I) Work Experience, Professional Background, and Concurrent Positions

Ms. Li Lihua, 61 years old, was appointed as an Independent Non-Executive Director of the Company on September 23, 2022. Her primary responsibility is to supervise the Board of Directors and provide independent opinions to the Board. Since October 2017, Ms. Li Lihua has been a lawyer at Beijing Huamao Guigu Law Firm. From March 1996 to October 2017, she served as a lawyer at Beijing Yongshen Law Firm, Beijing Guangsheng Law Firm, and Beijing Zhongyi Law Firm, respectively. From October 2016 to July 2020, she served as an Independent Non-Executive Director of this Company. Ms. Li Lihua obtained a Master of Laws degree from Peking University in July 1995.

(II) Statement on Independence

I do not hold any positions in the Company other than that of Independent Non-Executive Director. There are no circumstances that would hinder my independent and objective judgment. There are no situations that affect my independence as stipulated in the Administrative Measures for Independent Directors of Listed Companies, the Shenzhen Stock Exchange GEM Listing Rules for Regulated Operations, or the Hong Kong Stock Exchange Listing Rules.

I have conducted a self-assessment of my independence and confirmed that I meet the independence requirements for serving as an Independent Non-Executive Director as stipulated by applicable regulatory provisions. I have submitted the self-assessment results to the Board of Directors. The Board of Directors has evaluated my independence and found no circumstances that could affect my ability to conduct independent and objective judgment, concluding that I maintain my independence as an Independent Non-Executive Director.

II. Overview of Independent Non-Executive Director's Performance in the Reporting Year

(I) Attendance at Board Meetings and General Meetings

In 2025, the Company held 5 board meetings and 2 general meetings. My attendance at these meetings is as follows:

Independent Non-Executive DirectorNumber of Board Meetings to AttendNumber of Meetings Attended in PersonNumber of Meetings Attended by ProxyNumber of AbsencesConsecutive AbsencesAttended by ProxyNumber of General Meetings Attended
Li Lihua5500No2

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.